Q32 Bio Inc
$ 12.64
8.40%
02 Jun - close price
- Market Cap 187,368,000 USD
- Current Price $ 12.64
- High / Low $ 13.19 / 11.51
- Stock P/E 3.98
- Book Value 3.17
- EPS 2.78
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.19 %
- ROE 1.57 %
- 52 Week High 13.19
- 52 Week Low 1.34
About
Q32 Bio Inc. (QTTB) is an innovative biotechnology company specializing in the development of cutting-edge antibody-based therapies aimed at treating autoimmune diseases and optimizing immune responses. With its proprietary technology platform, Q32 Bio is advancing a diverse pipeline of therapeutic candidates poised to restore immune balance and address critical unmet medical needs. Supported by a highly experienced management team and strategic partnerships, Q32 Bio is strategically positioned to drive meaningful advancements in healthcare, ultimately creating long-term value for shareholders through its commitment to ongoing research and development excellence.
Analyst Target Price
$14.25
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-03-10 | 2025-11-13 | 2025-08-06 | 2025-05-08 | 2025-03-11 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-13 | 2023-11-14 | 2023-07-27 |
| Reported EPS | -0.54 | 4.58 | -0.6 | -0.78 | -0.9 | -1.16 | -1.457 | -1.42 | -14.95 | -0.28 | -0.57 | -0.61 |
| Estimated EPS | -0.68 | -0.86 | -1.19 | -0.8 | -1.23 | -1.53 | -1.4 | -1.04 | -2.32 | -0.3 | -0.43 | -0.5 |
| Surprise | 0.14 | 5.44 | 0.59 | 0.02 | 0.33 | 0.37 | -0.057 | -0.38 | -12.63 | 0.02 | -0.14 | -0.11 |
| Surprise Percentage | 20.5882% | 632.5581% | 49.5798% | 2.5% | 26.8293% | 24.183% | -4.0714% | -36.5385% | -544.3966% | 6.6667% | -32.5581% | -22% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: QTTB
2026-06-02 01:39:09
OrbiMed entities, including OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, and OrbiMed Genesis GP LLC, collectively acquired $15 million worth of Q32 Bio Inc. (NASDAQ:QTTB) common stock. The transaction involved 1,875,000 shares purchased at $8.00 each on May 28, 2026, as part of a private placement. Despite the stock showing a significant gain since the purchase, InvestingPro analysis suggests it is currently overvalued.
2026-06-02 01:10:05
Xu Diyong, a director and 10% owner of Q32 Bio Inc. (NASDAQ:QTTB), recently acquired 1,875,000 shares of the company's common stock for $15 million at $8.00 per share, through investment entities OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P. This significant insider purchase follows a 537% surge in Q32 Bio's stock over the past year, with the shares currently trading well above the purchase price. The company has also announced a $55 million private placement, filed for an at-the-market share offering, and received favorable analyst ratings for its lead program, bempikibart.
2026-06-02 01:10:05
OrbiMed Advisors LLC, OrbiMed Capital GP VII LLC, and OrbiMed Genesis GP LLC collectively invested $15 million in Q32 Bio Inc. common stock on May 28, 2026, purchasing 1.875 million shares at $8.00 each through a private placement. This transaction positions OrbiMed as a significant stakeholder, with one of its employees serving on Q32 Bio's board. The investment comes as Q32 Bio has seen a 46% gain since the transaction and a 537% return over the past year, alongside other recent financial and strategic developments.
2026-06-02 01:10:05
OrbiMed Advisors LLC and related funds have increased their stake in Q32 Bio Inc. (QTTB) to 17.4% following a May 2026 private placement. Through this PIPE, OrbiMed Private Investments VII, LP and OrbiMed Genesis Master Fund, L.P. acquired an additional 1.875 million shares at $8.00 per share. This transaction solidified OrbiMed's beneficial ownership to 4,127,987 common shares out of 23,681,415 shares outstanding.
2026-06-02 01:10:05
OrbiMed-affiliated funds have acquired 1,875,000 shares of Q32 Bio (QTTB) common stock at $8.00 per share in a private placement directly from the company. These transactions, totaling $15 million, increased OrbiMed's indirect holdings in Q32 Bio, indicating a significant investment directly into the company. OrbiMed entities are 10% owners and have a board representative at Q32 Bio.
2026-06-01 06:10:05
This document provides a company profile and introduction for Q32 Bio. The content is directly from a document format, implying a formal overview of the company.
